5San Miguel J F，Grit Rev Oncol Hematol，1996年，23卷，57页
6Hassn H T,Rees J K. Triple corabination of retinoic acid+ aclaci nomycin A+dimethylformanide induces differentiation of human acute leukemic blasts in primary culture anticancer [J]. Research, 1984,9 (3): 647-649.
1Jaffe ES,Harris NL,Stein H,et al.WHO classification of tumours:Pathology and genetics of tumours of hematopoietic lymphoid tissues[M].Lyon:IARC Press,2001:61～73.
2Kuriyama K,Tomonaga M,Matsuo T,et al.Poor response to intensive chemotherapy in de novo acute myeloid leukaemia with trilineage myelodysplasia.Japan Adult Leukaemia Study Group(JALSG)[J].Br J Haematol,1994,86(4):767～773.
3Greenberg P, Cox C, LeBeau MM, et al. international scoring system for evaluating prognosis in myelodysplastic syndromes [ J ]. Blood, 1997,89(6) :2079 -2088.
4Dayyani F, Conley AP, Strom SS, et al. Cause of death in patients with lower-risk myelodysplastic syndrome [ J ]. Cancer, 2010, 116 (9) :2174 -2179.
5Guillermo GM. Myelodysplastic syndromes:2011 update on diagno- sis, risk-stratification, and management [ J ]. Am J Hemato1,2011,86 (6) :491 -498.
6Takatoku M, Uehiyama T,Okamoto S,et al. Retrospective nationwide survey of Japanese patients with transfusion-dependent MDS and aplastic anemia highlights the negative impact of iron overload oil morbidity/mortality [ J ]. Eur J Haemato1.2007.78 (6) :487 - 494.
7Sanz G, Nomdedeu B, Such E, et al. Independent impact of iron o- verload and transfusion dependency on survival and leukemic evolu- tion in patients with myelodyspl.astic syndrome [ J ]. Blood, 2008, 112:640.
8Greenberg PL, Attar E, Bennett JM, et al. NCCN Clinical Practice Guidelines in Oncology:myelodysplastic syndromes[ J]. J Natl Corn-pr Cane Netw,2011,9(1) :30 -56.
10Sekeres MA, Schoonen WM, Kantarjian H, et al. Characteristics of US patients with myelodysplastic syndromes:Results of six cross- sectional physician surveys [ J]. J Natl Cancer Inst, 2008, 100 (21) :1542 - 1551.
